# Preemptive Infusion of Donor Lymphocytes Depleted of TCR + T Cells + CD19+ B Cells Following ASCT

> **NCT03939585** · PHASE1 · WITHDRAWN · sponsor: **Leland Metheny**

## Conditions studied

- Allogeneic Stem Cell Transplant Candidate
- Acute Myeloid/Lymphoblastic Leukemia
- Myelodysplastic Syndrome
- Myeloproliferative Neoplasm
- Lymphoproliferative Disorders

## Interventions

- **BIOLOGICAL:** Cellular therapy product

## Key facts

- **NCT ID:** NCT03939585
- **Lead sponsor:** Leland Metheny
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2024-12-01
- **Primary completion:** 2025-06-01
- **Final completion:** 2026-06-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Lack of funding
- **Last updated:** 2024-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03939585

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03939585, "Preemptive Infusion of Donor Lymphocytes Depleted of TCR + T Cells + CD19+ B Cells Following ASCT". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT03939585. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*